

Product datasheet for **TG309156**

SPATA2 Human shRNA Plasmid Kit (Locus ID 9825)

Product data:

Product Type:	shRNA Plasmids
Product Name:	SPATA2 Human shRNA Plasmid Kit (Locus ID 9825)
Locus ID:	9825
Synonyms:	PD1; PPP1R145; tamo
Vector:	pGFP-V-RS (TR30007)
E. coli Selection:	Kanamycin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	SPATA2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 9825). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.
RefSeq:	NM_001135773 , NM_006038 , NM_006038.1 , NM_006038.2 , NM_006038.3 , NM_001135773.1 , BC009481 , BC009481.2 , NM_006038.4
UniProt ID:	Q9UM82
Summary:	Bridging factor that mediates the recruitment of CYLD to the LUBAC complex, thereby regulating TNF-alpha-induced necroptosis (PubMed:27307491, PubMed:27458237, PubMed:27545878, PubMed:27591049). Acts as a direct binding intermediate that bridges RNF31/HOIP, the catalytic subunit of the LUBAC complex, and the deubiquitinase (CYLD), thereby recruiting CYLD to the TNF-R1 signaling complex (TNF-RSC) (PubMed:27458237, PubMed:27545878, PubMed:27591049). Required to activate the 'Met-1'- (linear) and 'Lys-63'-linked deubiquitinase activities of CYLD (PubMed:27458237, PubMed:27591049). Controls the kinase activity of RIPK1 and TNF-alpha-induced necroptosis by promoting 'Met-1'-linked deubiquitination of RIPK1 by CYLD (By similarity).[UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .


[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).